These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 27846724)

  • 1. [The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response].
    Zatloukalová P; Pjechová M; Babčanová S; Hupp TR; Vojtěšek B
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):72-77. PubMed ID: 27846724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
    Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
    Merelli B; Massi D; Cattaneo L; Mandalà M
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
    Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
    J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
    Hamid O; Carvajal RD
    Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.
    Black M; Barsoum IB; Truesdell P; Cotechini T; Macdonald-Goodfellow SK; Petroff M; Siemens DR; Koti M; Craig AW; Graham CH
    Oncotarget; 2016 Mar; 7(9):10557-67. PubMed ID: 26859684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
    Barsoum IB; Smallwood CA; Siemens DR; Graham CH
    Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
    Kerr KM; Nicolson MC
    Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer].
    Hamanishi J; Konishi I
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1071-6. PubMed ID: 25248890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
    Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG
    Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
    Swaika A; Hammond WA; Joseph RW
    Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research update on PD-1/PD-L1 pathway in hematological diseases].
    Li Y; Wang J; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1523-7. PubMed ID: 22169317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
    Jiang X; Wang J; Deng X; Xiong F; Ge J; Xiang B; Wu X; Ma J; Zhou M; Li X; Li Y; Li G; Xiong W; Guo C; Zeng Z
    Mol Cancer; 2019 Jan; 18(1):10. PubMed ID: 30646912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers.
    Guan J; Lim KS; Mekhail T; Chang CC
    Arch Pathol Lab Med; 2017 Jun; 141(6):851-861. PubMed ID: 28418281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis.
    Ooi JD; Li M; Kourkoutzelos K; Yagita H; Azuma M; Holdsworth SR; Kitching AR
    Nephrology (Carlton); 2015 Dec; 20(12):892-8. PubMed ID: 26043977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.
    He J; Hu Y; Hu M; Li B
    Sci Rep; 2015 Aug; 5():13110. PubMed ID: 26279307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 inhibition with MPDL3280A for solid tumors.
    Cha E; Wallin J; Kowanetz M
    Semin Oncol; 2015 Jun; 42(3):484-7. PubMed ID: 25965367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.